UBS Group Upgrades Otsuka (OTCMKTS:OTSKY) to “Hold”

Otsuka (OTCMKTS:OTSKY) was upgraded by analysts at UBS Group to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

OTSKY has been the subject of several other reports. Morgan Stanley raised Otsuka to an “overweight” rating in a research note on Friday, January 23rd. Zacks Research raised shares of Otsuka from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy”.

Otsuka Stock Down 0.3%

Shares of OTCMKTS OTSKY opened at $29.68 on Tuesday. The stock has a fifty day simple moving average of $28.96 and a 200-day simple moving average of $27.34. Otsuka has a twelve month low of $21.64 and a twelve month high of $30.64.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.